Caregen Co.,Ltd.

About Caregen Co.,Ltd.

Caregen is a publicly listed global leader in peptide biotechnology, headquartered in South Korea. Since 2001, the company has focused on advancing human health through peptide innovation, developing over 1,800 proprietary peptides and securing more than 860 global patents across pharmaceuticals, nutraceuticals, medical aesthetics, and cosmeceuticals.
Guided by its philosophy, “We don’t just add years, we redesign longevity,” Caregen is committed to scientific integrity, proven efficacy, and clinically validated peptide innovation.

Certifications
  • Country/Region:
    Korea, Republic Of
  • Founded:
    2001
  • On CPHI since:
    2016
  • Certificates:
    3
  • Employees:
    100 - 249
Company types
Biopharmaceutical company
Consumer Goods
Distributor/Import Export
Drug delivery device Supplier/Manufacturer
Manufacturer/Innovator
OTC
Other
Primary activities
API Producer
Biopharmaceutical
Cosmeceuticals
Cosmetic Ingredients
Nutraceuticals
OTC
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
Contact info
  • 23, Yeoksam-ro 98-gil, Gangnam-gu, 06188, Seoul, Republic of Korea, Korea, Republic Of
Meet us at

CPHI & PMEC China 2026

Shanghai New International Expo Center
16 Jun 2026 - 18 Jun 2026

CPHI South East Asia 2026

QSNCC, Bangkok, Thailand
08 Jul 2026 - 10 Jul 2026

CPHI Korea 2026

COEX, Seoul, Korea
25 Aug 2026 - 27 Aug 2026

CPHI Milan 2026

Fiera Milano, Italy
6 Oct 2026 - 8 Oct 2026

CPHI Middle East 2026

Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia
14 Dec 2026 - 16 Dec 2026

Products from Caregen Co.,Ltd. (6)

  • CG-P5

    Product CG-P5

    First-in-Class VEGFR2-Inhibiting Peptide Eye Drop for Wet Age-Related Macular Degeneration

    Product Overview: A New Standard for Non-Invasive Retinal Therapy
    CG-P5 is a first-in-class VEGFR2-inhibiting biomimetic peptide developed as a topical eye drop for the treatment of wet age-related m...
  • CG-T1

    Product CG-T1

    Peptide-Based Topical Therapeutic for Dry Eye Disease (DED)

    Product Overview: A Restorative Approach to Dry Eye Disease

    CG-T1 is a next-generation peptide-based topical therapy for dry eye disease, advancing toward Phase 2 clinical development in the United States following successfu...
  • Korglutide

    Product Korglutide

    Korglutide is a next-generation oral dual GLP-1R/IGF-1R peptide designed to support safe and muscle-preserving weight loss as a non-injectable nutraceutical alternative.
    Product Overview
    Korglutide is a synthetic dual GLP-1R and IGF-1R agonist peptide developed by Caregen for weight management and ...
  • MyoKi

    Product MyoKi

    MyoKi is an oral anti-myostatin peptide designed to support muscle mass and strength, enabling safe and effective muscle health management across all age groups.

    Product OverviewMyoKi is a peptide-based nutraceutical developed to support muscle preservation and functional performance t...
  • ProGsterol

    Product ProGsterol

    ProGsterol is an oral peptide-based nutraceutical designed to improve insulin receptor sensitivity and regulate glucose metabolism, supporting overall metabolic balance.
    Product Overview
    ProGsterol is a peptide-based nutraceutical developed by Caregen for metabolic disorders, including insulin re...
  • CG-Luxidase

    Product CG-Luxidase

    CG-Luxidase is a proprietary peptide-based delivery platform designed to enhance the penetration and distribution of active compounds by transiently modulating the hyaluronic acid (HA) network within the extracellular matrix (ECM).

    As a water-soluble synthetic decapeptide (INCI: Decapeptide-51),...

Caregen Co.,Ltd. Resources (1)